Department of Internal Medicine and Clinical Pharmacology, Medical University of Silesia, Medyków 18, PL 40-752 Katowice, Poland.
Pharmacol Rep. 2011;63(1):95-101. doi: 10.1016/s1734-1140(11)70403-0.
This study compared the effect of simvastatin on lymphocyte secretory function between patients with impaired glucose tolerance (IGT) (n=30) and mixed dyslipidemia (n=29). Lipid profile, glucose metabolism markers (fasting and 2-h post-glucose challenge glucose levels, HOMA-IR and glycated hemoglobin), plasma CRP levels and the release of interleukin-2 and interferon-γ by phytohemagglutinin-stimulated T lymphocytes were determined before and after 30 and 90 days of simvastatin administration (20 mg daily). Phytohemagglutinin-stimulated T cells from both IGT and mixed dyslipidemic subjects released significantly higher amounts of both cytokines than lymphocytes of 30 dyslipidemia-free individuals with normal glucose tolerance. Despite improving the lipid profile, simvastatin produced no effects on glucose metabolism markers in either treatment groups. The drug normalized the lymphocyte cytokine release and plasma hsCRP in mixed dyslipidemic patients but not in IGT patients. Our study indicates that the presence of mixed dyslipidemia and IGT is associated with the enhanced secretory function of human lymphocytes. Simvastatin is an effective lymphocyte-suppressing agent in mixed dyslipidemic patients but not in IGT patients.
本研究比较了辛伐他汀对糖耐量受损（IGT）（n=30）和混合性血脂异常（n=29）患者淋巴细胞分泌功能的影响。在辛伐他汀（每日 20mg）治疗前、后 30 和 90 天，分别测定了血脂谱、葡萄糖代谢标志物（空腹和葡萄糖负荷后 2 小时血糖水平、HOMA-IR 和糖化血红蛋白）、血浆 CRP 水平以及植物血凝素刺激的 T 淋巴细胞释放的白细胞介素-2 和干扰素-γ。与 30 例血脂正常、糖耐量正常的个体相比，IGT 和混合性血脂异常患者的植物血凝素刺激的 T 细胞释放的这两种细胞因子明显增多。尽管改善了血脂谱，但辛伐他汀对两组的葡萄糖代谢标志物均无影响。该药物使混合性血脂异常患者的淋巴细胞细胞因子释放和血浆 hsCRP 恢复正常，但对 IGT 患者无影响。我们的研究表明，混合性血脂异常和 IGT 的存在与人类淋巴细胞分泌功能增强有关。辛伐他汀是混合性血脂异常患者有效的淋巴细胞抑制药，但对 IGT 患者无效。
